AZIREST is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions: H. influenza, M. catarrhalis, S. pneumonia, C. pneumonia, M. pneumonia, S. pyrogenes, S. aureus, S.agal.
AZIREST binds to the 50S subunit of the 70S bacterial ribosomes, and therefore inhibits RNA-dependent protein synthesis in bacterial cells.
Bioavailability is 37% following oral administration. Absorption is not affected by food. AZIREST is extensively distributed in tissue with tissue concentrations reaching up to 50 times greater than plasma concentrations. Drug becomes concentrated within macrophages and polymorphonucleocytes giving it good activity against Chlamydia trachomatis. Volume of distribution: 31.1 L/kg Protein binding: Serum protein binding is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02µg/mL to 7% at 2µg/mL. Metabolism hepatic. Biliary excretion of AZIREST, predominantly as unchanged drug, is a major route of elimination. Half-life: 68 hours Clearance: apparent plasma cl= 630 mL/min
500mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections.
Each strip contains 10 capsules